Test to Classify Metastasis Risk in Prostate Cancers Validated by Study, GenomeDx Reports

Test to Classify Metastasis Risk in Prostate Cancers Validated by Study, GenomeDx Reports
GenomeDx Biosciences has announced the publication of a validation study of its Decipher Prostate Cancer Classifier, a genomic test for prostate cancer (PC) designed to improve clinical decisions regarding patient treatment and risk of metastasis following a diagnostic biopsy or radical prostatectomy (RP). The study “Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk,” was published in the journal Prostate Cancer and Prostatic Diseases. GenomeDx’s Decipher test includes Decipher Biopsy — used after a prostate cancer diagnosis — and Decipher Post-Op, which follows prostate surgery. The two commercially available tests provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. These tests are intended to help physicians stratify their patients by cancer risk to better determine those most likely to benefit from further treatment, and those at low risk of spread. Results from the retrospective study validated the clinical genomic risk assessment made by Decipher and CAPRA-S (Cancer of the Prostate Risk Assessment) — a score of potential prostate cancer recurrence based on pretreatment clinical data — on metastasis outcomes for patients receiving three different postoperative radiation therapies compared to observation alone. Data found that patients with lower clinico-genomic risks, as assessed by these scores, have excellent survival rates without any postoperative therapy, and those at higher risk have the best outcomes when given adjuvant radiation therapy early. "Treating prostate cancer patients according to a uniform strategy is inadequate, and can result in over- or under-treatment for many men," Ashley Ross, MD, the study's lead a
Subscribe or to access all post and page content.